Medical Distributors Surge: A Deeper Dive into Market Movements and Notable Tickers
π Medical Distributors experience a +3.18% gain in the past month. Current Buy/Sell Ratings suggest a Positive Outlook for stocks in the group.
Are you interested in the dynamic world of medical distributors and eager to optimize your trading strategies within this sector? Look no further! Our AI robots are tailored to meet your trading needs in the Group Medical Distributors arena.
π€ "Swing Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)" provides you with a reliable and data-driven approach to trading within this sector. Whether you're a seasoned trader or just starting, this AI tool can assist you in making informed decisions.
πΌ For those seeking to capitalize on upward market trends, "Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA)" offers a simplified yet effective strategy. It's designed to empower traders to navigate and thrive in markets on the rise.
With these AI robots by your side, you'll be well-equipped to explore trading opportunities and make data-backed decisions in the ever-evolving world of medical distributors. Elevate your trading game today!
Tickers in this Group:Β
$EDAPΒ - $CAHΒ - $MCKΒ - $CORΒ -Β $HSICΒ -Β $OMIΒ -Β $PDCOΒ - $ZYXI
The Landscape of Medical Distributors
Medical distributors play a pivotal role in the healthcare ecosystem, bridging the gap between manufacturers and providers. Their core services, ranging from product distribution to inventory management, contribute significantly to the US healthcare sector's value. As per a report by Deloitte, these services infuse a value of $33 billion-$53 billion annually. Major players in this sector include giants like McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc., and Patterson Companies, Inc.
Market Cap: The Financial Magnitude
The medical distributors' industry has a collective market cap averaging at 8.9B. The spectrum is vast - from $MCK at a towering 61.9B to a modest $SNYR at 494.4K.
High and Low Price Notable News: The Peaks and Valleys
Key Players:
Recent News Highlights:
Volume: The Trading Buzz
Fundamental Analysis Ratings: The Deep Dive
Ticker Descriptions: Highlighting Key Players
π $CAH: Now trending upward after rising above its 50-day MA on October 04, 2023. Past trends suggest a 78% chance of continued uptrend.
π $ZYXI: Watch out! Entering the oversold zone as of October 13, 2023. Historically, it indicates potential for a price uptrend or consolidation soon.
π $PDCO: Positive vibes! MACD Histogram turned positive on September 21, 2023, with 82% chances of a continued rise.
π $COR: Bullish trend with the 10-day MA crossing over the 50-day MA on September 28, 2023. Past data indicates a 71% chance of continued upward movement.
π $MCK: Yet another MACD positive shift on September 12, 2023, with a strong 75% odds of maintaining the bullish trend.
π $EDAP: Positive MACD crossover on September 20, 2023, suggests an 84% probability of an upward trend in the coming month.
Β
The Medical Distributors sector is currently buzzing with positive vibes, reflected in its impressive gains and overall positive outlook. Traders should closely monitor the described tickers and watch for further market shifts. As always, it's essential to make informed decisions and keep an eye on these notable market movers. Happy trading! πππ
The Aroon Indicator for EDAP entered a downward trend on December 17, 2024. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 185 similar instances where the Aroon Indicator formed such a pattern. In of the 185 cases the stock moved lower. This puts the odds of a downward move at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDAP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EDAP's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on December 20, 2024. You may want to consider a long position or call options on EDAP as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for EDAP just turned positive on December 17, 2024. Looking at past instances where EDAP's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDAP advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .
EDAP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EDAPβs price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.581) is normal, around the industry mean (7.608). EDAP's P/E Ratio (100.000) is considerably higher than the industry average of (28.511). EDAP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (4.521). EDAP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (4.303) is also within normal values, averaging (33.632).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDAPβs unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors